Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Oropharyngeal Neoplasms 1Mouth Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Carcinoma 1

Interventions

Cisplatin 57Radiotherapy 35Radiotherapy, Intensity-Modulated 30Magnetic Resonance Spectroscopy 24Radiation 21Carboplatin 19pembrolizumab 18Specimen Handling 16Platinum 14Cetuximab 141,2-diaminocyclohexaneplatinum II citrate 14Surveys and Questionnaires 13Paclitaxel 13Biopsy 11Surgical Procedures, Operative 10Fluorouracil 10Docetaxel 9Taxes 8Nivolumab 8Drug Therapy 8Chemoradiotherapy 8durvalumab 7Fluorodeoxyglucose F18 7Observation 6Blood Specimen Collection 6fludarabine 5X-Rays 5Immunohistochemistry 5Cyclophosphamide 5aldesleukin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Oropharyngeal Neoplasms × BAY 1895344 × Head & Neck × Clear all
NCT04576091 2024-12-13

Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
7 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡